Evogliptin-d9
Evogliptin-d9 (DA-1229-d9) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation[1][2][3][4].
Product Specifications
Product Name Alternative
DA-1229-d9
UNSPSC
12352005
Target
Autophagy; Dipeptidyl Peptidase; Isotope-Labeled Compounds
Related Pathways
Autophagy; Metabolic Enzyme/Protease; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Smiles
O=C1NCCN(C(C[C@H](N)CC2=CC(F)=C(F)C=C2F)=O)[C@@H]1COC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]
Molecular Formula
C19H17D9F3N3O3
Molecular Weight
410.48
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GRAMD4 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
Anti-Sialic Acid Binding Ig Like Lectin 2 (CD22) Monoclonal Antibody
Anti-Sialic Acid Binding Ig Like Lectin 2 (CD22) Monoclonal Antibody
Anti-Sialic Acid Binding Ig Like Lectin 2 (CD22) Monoclonal Antibody